N
17.96
-0.24 (-1.32%)
| Previous Close | 18.20 |
| Open | 19.01 |
| Volume | 1,006,111 |
| Avg. Volume (3M) | 896,650 |
| Market Cap | 2,016,387,072 |
| Price / Sales | 40.12 |
| Price / Book | 3.46 |
| 52 Weeks Range | |
| Earnings Date | 5 Aug 2025 - 11 Aug 2025 |
| Operating Margin (TTM) | -2,314.47% |
| Diluted EPS (TTM) | -1.84 |
| Quarterly Revenue Growth (YOY) | 112.60% |
| Total Debt/Equity (MRQ) | 0.05% |
| Current Ratio (MRQ) | 19.98 |
| Operating Cash Flow (TTM) | -140.43 M |
| Levered Free Cash Flow (TTM) | -99.00 M |
| Return on Assets (TTM) | -18.15% |
| Return on Equity (TTM) | -31.51% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | NewAmsterdam Pharma Company N.V | Bearish | Bullish |
AIStockmoo Score
0.8
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 0.5 |
| Average | 0.75 |
|
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 0.39% |
| % Held by Institutions | 111.32% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 45.00 (Wells Fargo, 150.56%) | Buy |
| Median | 41.00 (128.29%) | |
| Low | 27.00 (Goldman Sachs, 50.33%) | Hold |
| Average | 39.50 (119.93%) | |
| Total | 5 Buy, 1 Hold | |
| Avg. Price @ Call | 21.83 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Wells Fargo | 25 Aug 2025 | 45.00 (150.56%) | Buy | 24.70 |
| RBC Capital | 07 Aug 2025 | 39.00 (117.15%) | Buy | 22.96 |
| Goldman Sachs | 17 Jul 2025 | 27.00 (50.33%) | Hold | 21.98 |
| Citigroup | 17 Jun 2025 | 42.00 (133.85%) | Buy | 18.49 |
| Needham | 12 Jun 2025 | 40.00 (122.72%) | Buy | 21.03 |
| Stifel | 10 Jun 2025 | 44.00 (144.99%) | Buy | 21.84 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |